This product is a recombinant human anti-Hepatitis C virus monoclonal antibody. e20 specifically binds to glycoprotein E2 associated with HCV and can be potentially used in the treatment and diagnosis of Hepatitis C virus infection.
Figure 1 Neutralizing activity of Fab e20 using virus pseudoparticles (HCVpp).
The following strains were used: genotype 1a UKN1A20.8. Data obtained from HCVpp infection in the presence of different concentrations of c33-3 (negative control) and e20 are presented as a percentage of the infection detected in the absence of antibody. The means and standard errors of two replicate assays are reported.
Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes
Figure 2 Neutralizing activity of Fab e20 using the HCVcc system (genotype 2a).
The infectivity of JFH-1 in the presence of e20 and of negative-control Fab (c33-3) is presented as the viral RNA quantity normalized against glyceraldehyde-3-phosphate dehydrogenase RNA, as determined by quantitative reverse transcription-PCR. The means and standard errors of three replicate assays are reported.
Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes
Figure 3 Inhibition of binding of probe FLAG-Fab antigen by previous binding of different concentrations of purified unlabeled Fabs used as competitors.
Mapping B-Cell Epitopes of Hepatitis C Virus E2 Glycoprotein Using Human Monoclonal Antibodies from Phage Display Libraries
Figure 4 Inhibition of binding of human recombinant Fabs by previous binding of a 1:20 dilution of sera obtained from HCV-infected patients and from two HCV-negative controls.
All HCV-positive sera were demonstrated to contain HCV RNA of genotype 1b and to have an ELISA titer against HCV/E2 of>1:500.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MHH-446-F(E) | Recombinant Human Anti-HCV E2 Antibody Fab Fragment | WB, IHC, FuncS | Fab |
HPAB-0084-WJ-F(E) | Mouse Anti-HCV E2 Protein Recombinant Antibody; Fab Fragment (HPAB-0084-WJ-F(E)) | ELISA, WB | Mouse Fab |
HPAB-0085-WJ-F(E) | Mouse Anti-HCV E2 Protein Recombinant Antibody; Fab Fragment (HPAB-0085-WJ-F(E)) | ELISA, WB | Mouse Fab |
FAMAB-0174WJ-F(E) | Human Anti-HCV E2 Recombinant Antibody Fab Fragment (FAMAB-0174WJ-F(E)) | ELISA, WB, Neut | Human Fab |
PFBS-0067 | Human Anti-HCV E2 Recombinant Antibody (Clone HC84-26); Fab Fragment | ELISA, FuncS | Human Fab |
There are currently no Customer reviews or questions for MRO-1202LC. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.